However, in breast cancer, EZH2 acts as a dual-function transcriptional regulator with dynamic activity by transactivating estrogen and Wnt pathways via physically interacting directly with estrogen receptor and β-catenin to promote cell cycle progression [60]. Here, ESR1 is linked to breast cancer.